Imexpharm Corporation (HOSE:IMP)

Vietnam · Delayed Price · Currency is VND

37,650

+150 (0.40%)

At close: Aug 13, 2026

-28.96% (1Y)

Market Cap	5.80T -29.1%
Revenue (ttm)	2.32T -4.2%
Net Income	314.36B +0.7%
EPS	2,041.17 +1.4%
Shares Out	154.01M
PE Ratio	18.45
Forward PE	16.34
Dividend	500.00 (1.33%)
Ex-Dividend Date	Jul 13, 2026

Volume	43,495
Open	37,600
Previous Close	37,500
Day's Range	37,600 - 40,050
52-Week Range	32,650 - 57,000
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 16, 2026

About Imexpharm

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company’s products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm Corporation was founded in 1997 and is headquartered in Cao Lanh, Vietna... [Read more]

Industry Pharmaceutical Preparations

Founded 1997

Employees 1,438

Stock Exchange Ho Chi Minh Stock Exchange

Ticker Symbol IMP

Full Company Profile

Financial Performance

In 2025, Imexpharm's revenue was 2.44 trillion, an increase of 10.70% compared to the previous year's 2.21 trillion. Earnings were 304.39 billion, an increase of 10.34%.

Financial Statements